Citius Pharmaceuticals (CTXR) Expected to Announce Quarterly Earnings on Wednesday

Citius Pharmaceuticals (NASDAQ:CTXR) is expected to announce its earnings results on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.25) per share for the quarter.

Citius Pharmaceuticals Trading Down 3.7 %

Shares of CTXR stock opened at $2.59 on Wednesday. The business’s 50 day moving average is $3.32 and its two-hundred day moving average is $9.78. Citius Pharmaceuticals has a twelve month low of $2.44 and a twelve month high of $26.75. The company has a market capitalization of $22.25 million, a P/E ratio of -0.43 and a beta of 1.29.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on CTXR shares. HC Wainwright reiterated a “buy” rating and issued a $100.00 target price on shares of Citius Pharmaceuticals in a research note on Tuesday, November 12th. D. Boral Capital restated a “buy” rating and issued a $9.00 price target on shares of Citius Pharmaceuticals in a research note on Tuesday, January 7th.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.